MA57504B1 - Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide - Google Patents

Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide

Info

Publication number
MA57504B1
MA57504B1 MA57504A MA57504A MA57504B1 MA 57504 B1 MA57504 B1 MA 57504B1 MA 57504 A MA57504 A MA 57504A MA 57504 A MA57504 A MA 57504A MA 57504 B1 MA57504 B1 MA 57504B1
Authority
MA
Morocco
Prior art keywords
hydroxypyrrolidine
pyrazolo
difluorophenyl
pyrrolidin
pyrimidin
Prior art date
Application number
MA57504A
Other languages
French (fr)
Inventor
Alisha B Arrigo
Derrick Juengst
Khalid Shah
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA57504B1 publication Critical patent/MA57504B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une nouvelle forme cristalline de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)- l'invention concerne le 3-hydroxypyrrolidine-1-carboxamide, des compositions pharmaceutiques contenant ladite forme cristalline et l'utilisation de ladite forme cristalline dans le traitement de la douleur, du cancer, de l'inflammation, d'une maladie neurodégénérative ou d'une infection à trypanosoma cruzi. Dans certains modes de réalisation, la nouvelle forme cristalline comprend un polymorphe stable de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)-pyrazolo[1,5-a hydrogénosulfate de ]pyrimidine-3-yl)-3-hydroxypyrrolidine-1-carboxamide.A new crystal form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)- the invention relates to 3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or a trypanosoma cruzi infection. In some embodiments, the novel crystal form comprises a stable polymorph of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5 [a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate.

MA57504A 2014-11-16 2015-11-16 Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide MA57504B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462080374P 2014-11-16 2014-11-16

Publications (1)

Publication Number Publication Date
MA57504B1 true MA57504B1 (en) 2023-03-31

Family

ID=85793880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57504A MA57504B1 (en) 2014-11-16 2015-11-16 Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl hydrogen sulfate )-3-hydroxypyrrolidine-1-carboxamide

Country Status (1)

Country Link
MA (1) MA57504B1 (en)

Similar Documents

Publication Publication Date Title
PH12021550809A1 (en) Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA50817B1 (en) Forms and solid formulations of (s) -4- (8-amino-3- (1- (but-2-ynoyl) pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -n - (pyridin-2-yl) benzamide
CR20200064A (en) Carboxamides as modulators of sodium channels
JOP20220130A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
EA201492082A1 (en) CRYSTAL FORMS OF BLUTON TYROSINKINASE INHIBITOR
MX2021002321A (en) Novel methods.
MA34926B1 (en) EFFERVESCENT COMPOSITION IN SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS
EA200870396A1 (en) TREATMENT OF ALLERGY EYE DISEASES
FR3084254B1 (en) LANIFIBRANOR DERIVATIVES
MA44674A (en) BROMODOMAIN INHIBITORS
CL2008001114A1 (en) Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
EA201290131A1 (en) Derivatives of Purine or Deazapurine for Use in the Treatment of Viral Infections and Other Diseases
MA44610A (en) LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PYRROLIDIN-1-YL) -PYRAZOLO [1,5-A] PYRIMIDIN-3-YL) -3 -HYDROXYPYRROLIDINE-1-CARBOXAMIDE
EA201300471A1 (en) SUBSTITUTED 6-AMINONICOTINAMIDES AS KCNQ2 / 3 MODULATORS
EA201591541A1 (en) BETA SECRETASE INHIBITORS 1 (BACE 1)
MX386415B (en) USE OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL) PYRROLIDIN-1-YL)- PYRAZOLO [1,5-A] PYRIMIDIN-3-YL) -3-HYDROXYPYRROLIDINE-1- CARBOXAMIDE TO TREAT PEDIATRIC CANCERS.
EA201492097A1 (en) 5-AMINO [1,4] TIAZINS AS BETA SECRETASE INHIBITORS 1
EA201270602A1 (en) N - ((1R, 2S, 5R) -5- (TRET-BUTYLAMINO) -2 - ((S) -3- (7-TRET-BUTILPYRAZOLO [1,5-A] [1,3,5] TRIAZIN- 4-ILAMINO) -2-OXOPYRROLIDIN-1-IL) CYCLOGEXYL) ACETAMID AS A DUAL CHEMOKIN RECEPTOR ACTIVITY MODULATOR, ITS CRYSTALLINE FORMS AND METHOD
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA200901237A1 (en) APPLICATION OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN
AR062114A1 (en) MODULATORS OF THE ACTIVITY OF THE CHEMIOKIN RECEIVER, CRYSTAL FORMS AND PROCESSES.
MA39447B1 (en) Pirlindole or its pharmaceutically acceptable salts for use in medicine
MA39448B1 (en) (r) -pirlindole and its pharmaceutically acceptable salts for medical use
MA35064B1 (en) THIENO [2,3-D] PYRIMIDINE DERIVATIVES AND THEIR USE FOR TREATING ARRHYTHMIA
PL424452A1 (en) Inhibitors of inactive endopeptidase (NEP) and human soluble endopeptidase (hSEP) for prevention and treatment of eye diseases